奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HALO 奥洛兹美医疗

交易中 02-19 15:25:29 EST

72.03

-1.20

-1.64%

最高73.94	最低71.05	成交量196.03万
今开73.94	昨收73.23	日振幅3.95%
总市值84.71亿	流通市值83.55亿	总股本1.18亿
成交额1.41亿	换手率1.69%	流通股本1.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HALO","market":"US","secType":"STK","nameCN":"奥洛兹美医疗","latestPrice":72.03,"timestamp":1771532727666,"preClose":73.23,"halted":0,"volume":1960332,"delay":0,"changeRate":-0.01638672675133146,"floatShares":115999999,"shares":117597000,"eps":2.56,"marketStatus":"交易中","change":-1.2,"latestTime":"02-19 15:25:29 EST","open":73.94,"high":73.94,"low":71.05,"amount":140652291.94103998,"amplitude":0.039465,"askPrice":72.05,"askSize":671,"bidPrice":72.02,"bidSize":211,"shortable":0,"etf":0,"ttmEps":2.56,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1771534800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1099285200000,"exchange":"NASDAQ","adjPreClose":73.23,"preHourTrading":{"tag":"盘前","latestPrice":73.3497,"preClose":73.23,"latestTime":"09:28 EST","volume":1684,"amount":123320.38092000001,"timestamp":1771511313094,"change":0.1197,"changeRate":0.001635,"amplitude":0.007101},"postHourTrading":{"tag":"盘后","latestPrice":73,"preClose":73.23,"latestTime":"19:55 EST","volume":78815,"amount":5792193.0971,"timestamp":1771462515771,"change":-0.23,"changeRate":-0.003141,"amplitude":0.006787},"volumeRatio":0.775855,"impliedVol":0.3665,"impliedVolPercentile":0.2271},"requestUrl":"/m/hq/s/HALO/tweets","defaultTab":"tweets","newsList":[{"id":"1117593428","title":"奥洛兹美医疗发布全年营收展望：预计达13.85亿至14亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117593428","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117593428?lang=zh_cn&edition=full","pubTime":"2026-02-18 08:04","pubTimestamp":1771373095,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗公布了其新财年的营收预期，公司预计全年总收入将在13.85亿美元至14亿美元之间。这一展望反映了公司对其核心业务增长势头的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HALO","LU0053671581.USD"],"gpt_icon":0},{"id":"1111510374","title":"奥洛兹美医疗公布2025财年创纪录营收14亿美元，并重申2026年强劲财务指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1111510374","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111510374?lang=zh_cn&edition=full","pubTime":"2026-02-18 05:02","pubTimestamp":1771362164,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗公布了其2025财年的业绩，全年营收达到创纪录的14亿美元，彰显了公司强劲的增长势头。同时，公司管理层重申了对2026财年的积极财务展望，显示出对未来发展的坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","HALO"],"gpt_icon":0},{"id":"1169384348","title":"奥洛兹美医疗：预计到2026年底将有15个合作伙伴项目处于开发阶段；并签署三项或更多新型药物递送许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1169384348","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169384348?lang=zh_cn&edition=full","pubTime":"2026-01-28 19:33","pubTimestamp":1769599991,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗近日公布了其未来几年的战略发展目标。公司预计，到2026年底，其合作伙伴项目数量将达到15个，这些项目届时将处于不同的开发阶段。此外，该公司还计划签署至少三项新的药物递送技术许可协议，以进一步拓展其业务版图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"1100522345","title":"奥洛兹美医疗与武田达成全球合作，共同开发并商业化基于Enhanze®技术的维多珠单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=1100522345","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100522345?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:03","pubTimestamp":1767877380,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗（Halozyme Therapeutics）宣布，已与武田制药（Takeda）签署了一项全球合作与许可协议。根据该协议，双方将携手利用奥洛兹美的Enhanze®药物递送技术，共同开发并商业化其药物维多珠单抗（Vedolizumab）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","HALO","BK4139"],"gpt_icon":0},{"id":"1158508067","title":"Skye Bioscience Inc.计划于2026年年中启动Nimacimab联合Enhanze技术治疗肥胖症的2B期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1158508067","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158508067?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:03","pubTimestamp":1767614583,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc.近日公布其研发战略，计划在2026年中期正式启动一项针对肥胖症治疗的2B期临床试验。该试验将重点评估其核心候选药物Nimacimab与奥洛兹美医疗（Halozyme Therapeutics）专有的Enhanze药物递送技术联合应用的疗效与安全性。\n这一临床进展标志着Skye在代谢疾病治疗领域迈出了关键一步。Nimacimab作为一种创新疗法，结合Enhanze技术旨在增强药物递送效率，有望为肥胖患者提供新的治疗选择。公司预计该试验将为后续临床开发提供重要数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","HALO","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"1162485011","title":"奥洛兹美医疗与Skye Bioscience达成全球合作与许可协议，共同评估Nimacimab与Enhanze®复方制剂用于肥胖症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1162485011","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162485011?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:02","pubTimestamp":1767614523,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗与Skye Bioscience公司宣布，双方已签署一项全球性的合作与许可协议。该协议的核心内容是，将共同评估Nimacimab与奥洛兹美医疗的Enhanze®药物递送技术共同配制的复方制剂，用于治疗肥胖症的潜力。此次合作旨在结合两家公司的专长，探索这一创新疗法在代谢疾病领域的应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","HALO","BK4139","SKYE"],"gpt_icon":0},{"id":"1131503437","title":"美国FDA批准将Rybrevant Faspro™ (Amivantamab和Hyaluronidase-Lpuj)与Enhanze®联用治疗晚期EGFR突变非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1131503437","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131503437?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:02","pubTimestamp":1766059323,"startTime":"0","endTime":"0","summary":"美国FDA批准将Rybrevant Faspro™ (Amivantamab和Hyaluronidase-Lpuj)与Enhanze®联用治疗晚期EGFR突变非小细胞肺癌","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BK4139","HALO"],"gpt_icon":0},{"id":"1185472202","title":"Merus Nv：Halozyme将有权获得Petosemtamab净销售额的低至中个位数的版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1185472202","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185472202?lang=zh_cn&edition=full","pubTime":"2025-11-17 20:04","pubTimestamp":1763381051,"startTime":"0","endTime":"0","summary":"Merus Nv：Halozyme将有权获得Petosemtamab净销售额的低至中个位数的版税","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"1193904772","title":"Merus与奥洛兹美医疗达成全球合作和许可协议，共同开发皮下注射制剂Petosemtamab","url":"https://stock-news.laohu8.com/highlight/detail?id=1193904772","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193904772?lang=zh_cn&edition=full","pubTime":"2025-11-17 20:01","pubTimestamp":1763380901,"startTime":"0","endTime":"0","summary":"Merus与奥洛兹美医疗达成全球合作和许可协议，共同开发皮下注射制剂Petosemtamab","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"1142446305","title":"奥洛兹美医疗宣布定价私人发售6.5亿美元可转换优先票据，2023年到期和2032年到期各6.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142446305","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142446305?lang=zh_cn&edition=full","pubTime":"2025-11-07 12:38","pubTimestamp":1762490310,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗宣布定价私人发售6.5亿美元可转换优先票据，2023年到期和2032年到期各6.5亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"1162875334","title":"修正-奥洛兹美医疗第三季度收入3.543亿美元，超过Ibes预期的3.397亿美元（修正金额）","url":"https://stock-news.laohu8.com/highlight/detail?id=1162875334","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162875334?lang=zh_cn&edition=full","pubTime":"2025-11-04 06:34","pubTimestamp":1762209248,"startTime":"0","endTime":"0","summary":"修正-奥洛兹美医疗第三季度收入3.543亿美元，超过Ibes预期的3.397亿美元（修正金额）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"1198609488","title":"奥洛兹美医疗上调全年展望；财务主管将于明年三月离职","url":"https://stock-news.laohu8.com/highlight/detail?id=1198609488","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198609488?lang=zh_cn&edition=full","pubTime":"2025-11-04 05:25","pubTimestamp":1762205106,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗公司上调了其全年业绩展望，并宣布财务主管Nicole LaBrosse将离开公司，去追求新的机会。这家位于加利福尼亚的生物制药公司表示，LaBrosse将在公司找到新的财务主管之前继续留任，或在2026年3月30日之前离职。第三季度净收入增长至1.752亿美元，每股收益为1.43美元，较去年同期的1.37亿美元或每股1.05美元有所上升。奥洛兹美医疗上调了其全年经调整后的收益和收入预期。分析师预计今年的经调整后收益为每股6.13美元，收入为13.2亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","HALO","BK4139"],"gpt_icon":0},{"id":"1108896970","title":"奥洛兹美医疗第三季度调整后每股盈利1.72美元，超出IBES预期的1.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108896970","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108896970?lang=zh_cn&edition=full","pubTime":"2025-11-04 05:16","pubTimestamp":1762204564,"startTime":"0","endTime":"0","summary":"11月3日 - 奥洛兹美医疗第三季度净收入为1.75亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"1193530040","title":"奥洛兹美医疗提升2025年财务指引 并公布强劲的2025年第三季度财务与运营业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1193530040","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193530040?lang=zh_cn&edition=full","pubTime":"2025-11-04 05:02","pubTimestamp":1762203765,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗提升2025年财务指引，并公布强劲的2025年第三季度财务与运营业绩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"1147835631","title":"奥洛兹美医疗：若在特定情况下终止交易，公司将向Elektrofi支付3600万美元反向终止费","url":"https://stock-news.laohu8.com/highlight/detail?id=1147835631","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147835631?lang=zh_cn&edition=full","pubTime":"2025-10-04 04:55","pubTimestamp":1759524917,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗：若在特定情况下终止交易，公司将向Elektrofi支付3600万美元反向终止费","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","HALO","BK4139"],"gpt_icon":0},{"id":"1150582769","title":"Halozyme Therapeutics：预计交易对中期调整后稀释每股收益的稀释影响将低于5%，不包括潜在里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1150582769","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150582769?lang=zh_cn&edition=full","pubTime":"2025-10-01 19:06","pubTimestamp":1759316769,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics表示，预计相关交易对中期调整后稀释每股收益的稀释影响将低于5%，该预期不包括潜在的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"1177302172","title":"奥洛兹美医疗收购Elektrofi公司，扩展创新药物递送业务并强化2040年代长期增长前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1177302172","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177302172?lang=zh_cn&edition=full","pubTime":"2025-10-01 19:05","pubTimestamp":1759316704,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗收购Elektrofi公司，扩展创新药物递送业务并强化2040年代长期增长前景","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","HALO"],"gpt_icon":0},{"id":"2517912810","title":"传奥洛兹美医疗(HALO.US)将与默沙东(MRK.US)就注射版Keytruda展开专利战","url":"https://stock-news.laohu8.com/highlight/detail?id=2517912810","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517912810?lang=zh_cn&edition=full","pubTime":"2025-03-05 21:41","pubTimestamp":1741182111,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据报道，奥洛兹美医疗 与默沙东之间正在酝酿一场新的专利纠纷，争议的焦点是抗癌重磅药物Keytruda的注射版。知情人士透露，奥洛兹美医疗认为默沙东侵犯了其专利，应该签订许可协议才能销售注射用Keytruda。Keytruda几乎贡献了默沙东一半的总营收。默沙东去年表示，其注射版Keytruda在关键的3期试验中达到了主要目标。据报道，奥洛兹美医疗将在周三的投资者活动上讨论注射版Keytruda专利问题。截至发稿，默沙东盘前跌0.54%，奥洛兹美医疗涨0.81%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1571399168.USD","LU1291159041.SGD","LU1974910355.USD","LU2106854487.HKD","LU0238689110.USD","BK4007","LU1035773651.USD","LU1983299246.USD","LU2089984988.USD","SG9999013999.USD","IE0002141913.USD","LU1093756168.USD","HALO","LU0965509101.SGD","LU1066053197.SGD","SG9999015358.SGD","IE00BSNM7G36.USD","LU1116320737.USD","LU0053671581.USD","LU0122379950.USD","BK4534","LU1066051225.USD","IE00BJT1NW94.SGD","LU1066051498.USD","BK4139","LU1989772840.SGD","LU2023250843.SGD","LU1934455194.USD","LU1917777945.USD","IE00B1BXHZ80.USD","LU1934455277.USD","LU1989772923.USD","LU0203347892.USD","SG9999014575.USD","MRK","LU1162221912.USD","LU1023059063.AUD","LU0965509283.SGD","LU1066051811.HKD","LU0965509010.AUD","LU1585245621.USD","LU1699723380.USD","LU2023250504.SGD","LU1037948897.HKD","LU1093756325.SGD","SG9999002232.USD","SG9999015341.SGD","SG9999002224.SGD","LU0265550359.USD","IE00BBT3K403.USD"],"gpt_icon":0},{"id":"2513292619","title":"奥洛兹美医疗2024财年实现净利润4.44亿美元，同比增加57.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513292619","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513292619?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:00","pubTimestamp":1740153649,"startTime":"0","endTime":"0","summary":"2月22日，奥洛兹美医疗公布财报，公告显示公司2024财年净利润为4.44亿美元，同比增加57.45%；其中营业收入为10.15亿美元，同比增加22.44%，每股基本收益为3.50美元。从资产负债表来看，奥洛兹美医疗总负债18.00亿美元，其中短期债务7.05百万美元，资产负债比为1.21，流动比率为7.81。机构评级：截至2025年2月22日，当前有9家机构对奥洛兹美医疗目标价做出预测，其中目标均价为66.11美元，其中最低目标价为53.00美元，最高目标价为78.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000113abd7c32f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000113abd7c32f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HALO"],"gpt_icon":0},{"id":"2512395109","title":"HC Wainwright & Co.：维持Halozyme Therapeutics(HALO.US)评级，由买入调整至买入评级, 目标价由70.00美元调整至72.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512395109","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512395109?lang=zh_cn&edition=full","pubTime":"2025-02-19 20:24","pubTimestamp":1739967879,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Halozyme Therapeutics(HALO.US)评级，由买入调整至买入评级, 目标价由70.00美元调整至72.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19202448265683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HALO","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.halozyme.com","stockEarnings":[{"period":"1week","weight":-0.079},{"period":"1month","weight":0.0284},{"period":"3month","weight":0.0618},{"period":"6month","weight":0.0196},{"period":"1year","weight":0.2648},{"period":"ytd","weight":0.0881}],"compareEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0064}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Halozyme Therapeutics, Inc.是一家生物制药公司,成立于1998年。2007年11月，该公司重组并注册于特拉华州（以前注册于内华达州）。该公司致力于创新产品的开发和商业化。公司研究细胞外基质、细胞外区域,包括细胞迁移、信号和存活。多年来,该公司已经开发了独特的科学专业知识, 允许其追求侧重于环境发展的治疗办法。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.005218},{"month":2,"riseRate":0.636364,"avgChangeRate":0.025132},{"month":3,"riseRate":0.52381,"avgChangeRate":0.043178},{"month":4,"riseRate":0.590909,"avgChangeRate":-0.006442},{"month":5,"riseRate":0.545455,"avgChangeRate":0.005082},{"month":6,"riseRate":0.590909,"avgChangeRate":0.043711},{"month":7,"riseRate":0.636364,"avgChangeRate":0.034998},{"month":8,"riseRate":0.5,"avgChangeRate":-0.00554},{"month":9,"riseRate":0.363636,"avgChangeRate":0.020207},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.027834},{"month":11,"riseRate":0.636364,"avgChangeRate":0.065813},{"month":12,"riseRate":0.545455,"avgChangeRate":0.110354}],"exchange":"NASDAQ","name":"奥洛兹美医疗","nameEN":"Halozyme Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥洛兹美医疗(HALO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥洛兹美医疗,HALO,奥洛兹美医疗股票,奥洛兹美医疗股票老虎,奥洛兹美医疗股票老虎国际,奥洛兹美医疗行情,奥洛兹美医疗股票行情,奥洛兹美医疗股价,奥洛兹美医疗股市,奥洛兹美医疗股票价格,奥洛兹美医疗股票交易,奥洛兹美医疗股票购买,奥洛兹美医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥洛兹美医疗(HALO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}